CiteSpace-based Visualization of Xanthone Capsule for Diabetic Nephropathy Treatment

Xiaoqing Feng; Li Liu

Authors

Xiaoqing Feng The First Clinical School of Medicine, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
Li Liu The First Clinical School of Medicine, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China

Keywords:

Diabetic kidney disease (DKD), Huangkui Capsule, Research hotspots, Visual analysis, CiteSpace

Abstract

Objective: To conduct a visual analysis of research hotspots and trends in the treatment of diabetic kidney disease (DKD) with Huangkui Capsule using CiteSpace visualization software. Methods: Relevant literature on the treatment of DKD with Huangkui Capsule was retrieved from China National Knowledge Internet (CNKI). Co-occurrence and clustering analyses were performed on keywords, authors, and publishing institutions. Additionally, burst analysis and timeline visualization were applied to keywords, and a visual analysis of annual publication volume was conducted to explore research hotspots and development trends. Results: A total of 289 articles were included in this study. The annual publication volume showed an upward trend from 2007 to 2010 and from 2013 to 2017, with a decline after 2020. However, the overall trend before 2020 was an increase in annual publications. Author collaborations, exemplified by Liu Rongjuan, Wan Yigang, and Sun Wei, were prevalent. Inter-institutional collaborations were less pronounced. The clustering of keywords yielded eight clusters labeled as adverse reactions, proteinuria, valsartan, renal function, oxidative stress, clinical efficacy, treatment group, and targets. Burst analysis identified 78 burst terms, among which urea nitrogen, dapagliflozin, inflammatory markers, adverse reactions, signaling pathways, and targets emerged as new research hotspots. Conclusion: The primary research focus on the treatment of DKD with Huangkui Capsule centers on clinical randomized controlled trials, particularly those combining Huangkui Capsule with valsartan, dapagliflozin, liraglutide, or traditional Chinese medicine formulations. Clinical studies remain the dominant research type. Currently, there is a lack of in-depth basic research, and more standardized clinical and basic research is needed to provide evidence-based medical support in this field. Incorporating the expertise of renowned practitioners with Chinese medicine characteristics can offer additional insights for clinical treatment.

References

Expert Panel of Nephrology Branch, Chinese Medical Association. Chinese Guidelines for Clinical Diagnosis and Treatment of Diabetic Kidney Disease. Chinese Journal of Nephrology, 2021, 37(03): 255-304.

Afkarian M, Zelnick LR, Hall YN, et al. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. JAMA, 2016, 316(6): 602-610.

de Boer IH, DCCT/EDIC Research Group. Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2014, 37(1): 24-30.

Luk A, Hui E, Sin MC, et al. Declining Trends of Cardiovascular-Renal Complications and Mortality in Type 2 Diabetes: The Hong Kong Diabetes Database. Diabetes Care, 2017, 40(7): 928-935.

Chan JC, So W, Ma RC, et al. The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry. Current Cardiovascular Risk Reports, 2011, 5(3): 230-239.

Luk AO, Ma RC, Lau ES, et al. Risk Association of HbA1c Variability with Chronic Kidney Disease and Cardiovascular Disease in Type 2 Diabetes: Prospective Analysis of the Hong Kong Diabetes Registry. Diabetes Metabolism Research and Reviews, 2013, 29(5): 384-390.

Thomas MC, Brownlee M, Susztak K, et al. Diabetic Kidney Disease. Nature Reviews Disease Primers, 2015, 1: 15018.

Committee of Endocrinology and Metabolism, Chinese Association of Integrated Traditional and Western Medicine Physicians, Yu JY, Ni Q, et al. Guidelines for Diagnosis and Treatment of Diabetic Nephropathy Based on Disease-Syndrome Combination. Journal of Traditional Chinese Medicine, 2022, 63(2): 190-197. (ISTIC PKU CSCD, 2022)

Su QM, Meng HM, Zhang QF, Liu RJ. Effects of Huangkui Capsule on Vascular Endothelial Function in Patients with Diabetic Nephropathy. Journal of Rational Use of Drugs in Clinics, 2015, 8(07): 63-64.

Su QM, Meng HM, Zhang QF, Liu RJ. Protective Effects of Huangkui Capsule on Patients with Diabetic Nephropathy. Journal of Rational Use of Drugs in Clinics, 2015, 8(10): 47-48.

Su QM, Meng HM, Zhang QF, Liu RJ. Effects of Huangkui Capsule on Inflammatory Response and Lipid Levels in Patients with Diabetic Nephropathy. Journal of Rational Use of Drugs in Clinics, 2015, 8(04): 95+97.

Mao ZM, Wan YG, Sun W, Chen HL, Huang YR, Shi XM, Yao J. Inhibition of Oxidative Stress and p38MAPK Signaling Pathway Activity by Huangkui Capsule in Renal Tissue of Diabetic Nephropathy and Its Effect on Renal Fibrosis. China Journal of Chinese Materia Medica, 2014, 39(21): 4110-4117.

Wu W, Liu YL, Wan YG, Cao DW, Fang QJ, Tu Y, Liu BW, Wang WW, Wang MZ, YEE Hong-yun, Yuan CC, Hu W. Multi-Target Therapeutic Effects of Huangkui Capsule on Insulin Resistance and Urinary Microalbumin in Patients with Early Diabetic Kidney Disease. China Journal of Chinese Materia Medica, 2020, 45(23): 5797-5803.

Chen, P., Wan, Y.G., Wang, Z.J., Zhao, Q., Wei, Q.X., Tu, Y., Yin, X.J. (2012). Mechanisms and efficacy of Abelmoschus manihot flower preparations in the treatment of chronic kidney disease. China Journal of Chinese Materia Medica, 37(15), 2252-2256.

Li, N., Lv, D., Zhu, X.J., Wei, P., Zhang, L., He, W.M., Zhou, E.C., Sun, W. (2022). Network meta-analysis of three commonly used traditional Chinese medicine preparations for the treatment of stage III diabetic nephropathy. Chinese Journal of Integrated Traditional and Western Nephrology, 23(03), 240-244.

Mao, Z.M., Wan, Y.G., Sun, W., Chen, H.L., Huang, Y.R., Shi, X.M., Yao, J. (2014). Effects and mechanisms of Huangkui Capsule in inhibiting oxidative stress and p38MAPK signaling pathway activity in renal tissue of diabetic nephropathy to improve renal fibrosis. China Journal of Chinese Materia Medica, 39(21), 4110-4117.

Liu, H., Sun, W., Gu, L.B., Tu, Y., Hu, H. (2015). Meta-analysis of Huangkui Capsule combined with ACEI or ARB in the treatment of diabetic nephropathy. China Journal of Traditional Chinese Medicine and Pharmacy, 30(05), 1712-1718.

Mao, Y.Y., Li, H.F., Xia, Z.S., Zhao, H. (2019). Observation on the efficacy of Calcium Dobesilate combined with Huangkui Capsule in the treatment of early diabetic nephropathy. Clinical Research, 27(11), 125-126.

Hou, J. (2020). Effect of Huangkui Capsule combined with Tripterygium Glycosides and Valsartan in the treatment of patients with stage IV diabetic nephropathy. Henan Medical Research, 29(22), 4145-4147.

Xue, X.X. (2020). Analysis of the efficacy of Huangkui Capsule combined with Alprostadil in the treatment of diabetic nephropathy. Diabetes New World, 23(23), 177-179.

Yang, J. (2017). Clinical observation on the treatment of early diabetic nephropathy proteinuria with Huangkui Capsule combined with Bailing Capsule. Chinese Journal of Medicinal Guides, 19(07), 717+719.

Qimge, Yu, H.Y., Li, R.Y. (2016). Clinical efficacy analysis of valsartan combined with Huangkui Capsule in the treatment of early diabetic nephropathy. Inner Mongolia Medical Journal, 48(03), 296-298.

Liu, Y.Y., Cao, W. (2019). Observation on the efficacy of Alprostadil combined with Valsartan and Huangkui Capsule in the treatment of diabetic nephropathy proteinuria. Journal of Clinical Medical Literature, 6(14), 96-97.

He, L.F., Li, Q.K., Xue, Y.Y., Ren, P.X., Ma, Y.X., Yan, S.H. (2023). Effect of adjuvant treatment with Huangkui Capsule on urinary protein excretion rate and oxidative stress in patients with early diabetic nephropathy. China Medical Herald, 20(12), 90-93.

Zhai, Y.Y., Li, C.G. (2020). Clinical effect of Huangkui Capsule as adjuvant therapy for diabetic nephropathy and its influence on renal tubular injury and oxidative stress. Clinical Research and Practice, 5(33), 143-145.

Sha, Q., Zong, Y., Zhao, Y., Feng, Y.H., Yang, M., Wang, X.S. (2021). Impact of Huangkui Capsule on intestinal flora in diabetic nephropathy and its underlying mechanisms. Chinese Archives of Traditional Chinese Medicine, 39(04), 196-199.

Fang, Y.F. (2021). Effects of Huangkui Capsule on renal tubular injury and oxidative stress markers in patients with diabetic nephropathy. Henan Medical Research, 30(26), 4928-4930.

Li, Z.Y., Xie, J. (2014). Clinical efficacy of Huangkui Capsule in the treatment of early to mid-stage diabetic nephropathy and its influence on blood lipid levels. Chinese Journal of Basic Medicine in Traditional Chinese Medicine, 20(02), 200-201+210.

Chu, F., Liang, W., Liu, Z.K., Hu, H.T., Zhang, Z.W., Ding, G.H. (2023). Efficacy and safety analysis of Dapagliflozin in treating edema in patients with diabetic kidney disease at different renal function statuses. Journal of Clinical Nephrology, 23(07), 575-584.

Yang, D.Y., Cen, J., Luo, Q., et al. (2023). Effect of Huangkui Capsule combined with Dapagliflozin on Cys-C and α1-MG in patients with early diabetic nephropathy. China Modern Medicine, 17(10), 29-33.

Liu, H., Sun, W., Gu, L.B., et al. (2015). Meta-analysis of Huangkui Capsule combined with ACEI or ARB in the treatment of diabetic nephropathy. China Journal of Traditional Chinese Medicine and Pharmacy, 30(05), 1712-1718.

Zhu, Q.W. (2023). Clinical value of Huangkui Capsule combined with Liraglutide in the treatment of patients with early diabetic nephropathy. China Modern Medicine, 17(17), 135-137.